AbD Serotec Enters New Growth Area
News May 18, 2010
MorphoSys AG has announced that its research and diagnostic antibody unit AbD Serotec is active in a new growth area. AbD Serotec is increasingly providing anti-idiotype antibodies against existing antibody drugs and drug candidates to accompany their preclinical and clinical development.
AbD Serotec already provides anti-idiotype antibodies to several international pharmaceutical and biotechnology companies. Additionally, anti-idiotype antibodies produced by AbD Serotec are being used in-house to support MorphoSys’s proprietary development programs in cancer and inflammatory diseases.
The growing number of therapeutic antibodies in clinical development is driving the demand for tools to monitor their concentration and behavior in patients, including critical parameters such as pharmacokinetics and immunogenicity. Since the majority of antibody-based drug candidates in clinical trials today is fully human, the detection tools must differentiate between the drug and other antibodies present in patient serum or plasma samples.
HuCAL-based anti-idiotype antibodies are ideal tools to detect the respective drug candidate with very high sensitivity. With its fully recombinant HuCAL technology, AbD Serotec can provide these tools quickly, allowing their customers to develop assays for non-clinical and clinical samples in a very short time frame. The HuCAL platform delivers fully human antibodies, a key factor for immunogenicity assays. At the same time, the antibodies have a high affinity for their targets, which is a prerequisite to reach the necessary sensitivity in a final assay.
“We see tools supporting preclinical research and clinical trials as a real growth opportunity, in which we can deliver solutions with our cutting-edge antibody technology,” commented Dieter Feger, Head of AbD Serotec. “The use of recombinant technology is a major advantage that positions us well in this growing market.”
“Anti-idiotype antibodies represent an important synergy between our therapeutic and non-therapeutic business units,” commented Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG. “AbD Serotec now broadly supports our proprietary development programs, providing high quality analytical tools with excellent sensitivity for our pre-clinical and clinical work.”
Protein Target Identified That Could Prevent StrokesNews
Scientists have identified a protein, called GPR68, that senses blood flow and tells small blood vessels called arterioles when to dilate. The researchers believe medications that activate GPR68 could one day be useful to treat medical conditions, including ischemic stroke.READ MORE
Reversing an Unstoppable Cancer Cascade with ProteomicsNews
Mutations in genes that produce RAS proteins turn a normally benign process, essential for cellular growth, into a cancer stimulant that is currently undruggable. Now, cutting-edge protein analysis may help treat cancers caused by these mutations.READ MORE
The Protein and the PauparNews
Non-coding RNAs (ncRNA) exist in a limbo within cells, having been created from genes but never destined to be turned into functional protein. A ncRNA called Paupar has been shown to regulate a protein controlling brain growth, a first for these mysterious molecules.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018